Illumina announced the commercial launch of its Protein Prep solution on November 10 2025, adding a high‑throughput proteomics platform to its existing sequencing portfolio. The new kit uses SOMAmer® aptamer technology to quantify more than 9,500 unique proteins from a single blood sample, and it is integrated with Illumina’s sequencing instruments and DRAGEN analytics to create a unified multi‑omics workflow.
The platform’s coverage is the broadest available for blood proteomics, and it offers the lowest cost per protein target on the market. Compared with earlier versions that measured roughly 6,000 targets, the current assay delivers a 50 % increase in depth while maintaining a competitive price point, positioning Illumina as a viable alternative or complement to mass‑spectrometry‑based proteomics.
Illumina’s early‑access program, which began in early 2025, has already engaged nearly 40 research groups and processed more than 40,000 samples. The first Asia Pacific site to adopt the kit is Sydney Mass Spectrometry, and the product is now available at 16 sites worldwide. These early adopters are using the platform to accelerate biomarker discovery, drug target validation, and precision‑medicine studies.
The launch is a key milestone in Illumina’s multi‑omics strategy and dovetails with its pending acquisition of SomaLogic, which is expected to close in the first half of 2026. By combining genomics, transcriptomics, and proteomics in a single workflow, Illumina aims to deepen customer stickiness, open new revenue streams, and provide a more comprehensive view of biological systems for both clinical and research applications.
Analysts have highlighted the launch as a significant expansion of Illumina’s product portfolio. The move is expected to strengthen the company’s competitive position against traditional proteomics vendors and to support the broader adoption of multi‑omics approaches in drug discovery and personalized medicine.
Looking ahead, Illumina plans to scale the Protein Prep platform through additional site deployments and to integrate the technology with its cloud‑based data analytics services. The company’s focus on cost efficiency, high‑throughput processing, and seamless integration with existing sequencing workflows is expected to drive adoption and revenue growth in the coming years.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.